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The role of probiotics on the microbiota: effect on obesity. 
Abstract 
The microbiota and the human host maintain a symbiotic association. Nowadays, 
metagenomic analyses are providing valuable knowledge on the diversity and 
functionality of the gut microbiota. However, with regards to the definition of a 
“healthy microbiota” and the characterization of the dysbiosis linked to obesity, there is 
still not a clear answer. Despite this fact, attempts have been made to counteract obesity 
through probiotic supplementation. A literature search of experimental studies relevant 
to the topic was performed in PubMed database with the keywords “probiotic” and 
“obesity” and restricted to those with “Lactobacillus” or “Bifidobacterium” in the title. 
So far, evidence of an anti-obesity effect of different lactobacilli and bifidobacteria has 
been mainly obtained from animal models of dietary-induced obesity. Using these 
experimental models, a substantial number of studies have reported reductions in weight 
gain and in particular in fat tissue mass at different locations following administration of 
bacteria, compared to controls. Anti-atherogenic and anti-inflammatory effects 
including regulation of expression of lipogenic and lipolytic genes in the liver, reduction 
in liver steatosis, improvement of blood lipid profile and glucose tolerance, decreased 
endotoxemia and regulation of inflammatory pathways are also reported in many of 
them. The number of human studies focused on probiotic administration for obesity 
management is still very scarce, and it is too soon to judge their potential efficacy, 
especially considering the fact that the actions of probiotics are always strain–specific, 
and the individual response varies according to intrinsic factors, the overall composition 
of diet and their interactions.  
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Introduction 
Intestinal microbiota and the individual have evolutionarily set up a symbiotic 
association that allowed them to reach functional stability. The intestinal microbiota 
performs a series of metabolic functions necessary to the living organism. Among 
others, microbiota is involved in energy harvest from diet through the utilization of 
indigestible compounds, vitamin synthesis, micronutrient absorption, xenobiotic 
biotransformation, immune system stimulation and pathogen resistance1 . Gut 
microbiota harbors 1014 bacteria, ten-fold the number of human cells, and includes up to 
2000 species2. The diversity of microbes within a given body habitat can be defined as 
the number and abundance distribution of distinct types of organisms. A low diversity 
has been linked to obesity and inflammatory bowel disease, according to evidence 
derived from modern techniques of 16S ribosomal RNA gene (rRNA) sequencing and 
metagenomic sequencing3,4. 
While human gut microbiota seems to be fairly stable over time, between-subject 
variation, even among healthy individuals, is bigger, both in organismal composition 
and in metabolic function5 . It has been suggested that human gut microbiomes fall into 
three distinct types or “enterotypes”, robust clusters identifiable by the variation in the 
levels of one of three genera: Bacteroides (enterotype 1), Prevotella (enterotype 2) and 
Ruminococcus (enterotype 3)6 . However, most human gut microbiome data collected to 
date support continuous gradients of dominant taxa rather than discrete enterotypes7 .   
Methods based on16S rRNA sequencing revealed that two bacterial divisions, the 
Bacteroidetes and the Firmicutes, constitute over 90% of the known phylogenetic 
categories and dominate the distal gut microbiota8. The gut microbial gene catalog 
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established by metagenomic sequencing as part of the MetaHIT project revealed that the 
studied cohort harbored between 1000 and 1150 prevalent bacterial species, and each 
individual at least 160 such species, which are also largely shared4 . As sequencing and 
analysis progresses, it seems that a core of microbial species might be common to all 
individuals and high variability might exist in their specific abundances. In addition, 
clusters of related species have been found in the MetaHit project which include some 
of the most abundant gut species belonging to Bacteroidetes and 
Dorea/Eubacterium/Ruminococcus groups and also bifidobacteria, proteobacteria and 
streptococci/lactobacilli groups. Among commensals, lactic acid bacteria are species of 
the acidophilus complex, a diverse group of Gram-positive, non-spore forming, 
facultatively anaerobic bacteria that have a G+C content of less than 50% and produce 
lactic acid by fermentation. These includes Lactobacillus acidophilus, Lactobacillus 
gasseri, Lactobacillus johnsonii and other related lactobacilli which have proven to be 
microorganisms with probiotic attributes9 . As commensals, they have the capacity to 
occupy mucosal niches of humans, including the oral cavity, the gastrointestinal tract 
and the vagina.  
Probiotics are live micro-organisms that, when administered in adequate amounts, have 
been shown to confer health benefits to the host10 (FAO/WHO, 2001). In general, those 
more frequently employed belong to the Lactobacillus and Bifidobacterium genera, 
which are common inhabitants of the human intestinal ecosystem. Some of the benefits 
supported by stronger evidence include: improvements of lactose intolerance and 
digestive symptoms of discomfort, and reduction of risk of antibiotic-associated 
diarrhea and necrotizing enterocolitis; and with a lower degree of certainty, some 
probiotics have been shown to improve immune response to vaccines, infant’s eczema, 
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vaginal infections, and to alleviate allergy symptoms and inflammatory bowel disease11. 
However, scientific agreement on probiotic applications for health is difficult to 
achieve. In the first place, effects are strain-specific, and secondly, the scientific studies 
performed on any given benefit for health provide graded evidence that depends on 
quality criteria applied to human clinical trials, such as demonstration of the benefit in 
the target population in a well-controlled, blinded, randomized manner. A positive 
balance between high-quality independent studies showing positive results and those 
showing no effects or negative results is necessary. Thus, more research should be 
conducted in the probiotic field in order to understand the potential of these health-
promoting microorganisms for humans. A literature search of experimental studies 
relevant to the topic was performed in PubMed database with the keywords “probiotic” 
and “obesity” and restricted to those with “Lactobacillus” or “Bifidobacterium” in the 
title to focus on the genera that provide the bulk of the information on the topic.   
Secondly, further relevant articles were retrieved by a broader search with combinations 
of some of the keywords and adding the term “microbiota”.   
Interaction of probiotics with host cells and commensal microbiota 
To be considered a good probiotic candidate, a bacterial strain should present some 
characteristics that contribute to indigenous colonization, such as tolerance to low pH, 
resistance to bile salts and adhesion to the host epithelium9. Based on their long 
tradition of use without any harmful effects on human health, lactic acid bacteria of the 
Lactobacillus and Bifidobacterium genera have an established safety record and have 
been accorded the GRAS (Generally Recognized As Safe) status by the Food and Drug 
Administration (FDA, USA). 
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A principal role of the microbiota is the participation in immune system development 
during the early stages of life12. In parallel, immune homeostasis, achieved through 
interactions with the resident microbiota is fundamental to avoid uncontrolled 
inflammatory responses and pathologies13. 
Probiotics, either colonizing or in transit, interact with the host in several manners with 
effects such as: 1) modulation of endogenous microbiota functions affecting its 
interplay with the host and the competitive exclusion of pathogens, 2) enhancement of 
epithelial barrier function and other innate immune responses; and 3) modulation of 
immune cell behavior and cytokine profiles14. An important part of the interactions 
occurs through the microbe-associated molecular patterns (MAMP) in the microbiota, 
such as cell wall and cytoplasmic membrane anchored molecules (polysaccharides, 
peptidoglycans, lipoproteins and lipoteichoic acids), which are recognized by pattern 
recognition receptors (PRRs) expressed in epithelial, immune and other host cells (i.e.
Toll-like receptors [TLRs] )14. Although these MAMPs appear to be produced by many 
different lactobacilli, their chemical structure may still vary between strains in terms of 
polymer composition, length and substitutions, which may explain part of the strain 
specificity of probiotics. Lactobacilli, indeed, differ considerably in their ability to 
trigger TLR2 signaling15.  
Genome sequencing and functional genomics of bifidobacteria have significantly 
expanded our understanding regarding the roles of gut-derived bifidobacteria in both 
microbe-microbe and host-microbe interactions through molecules that facilitate their 
establishment in the human intestine. These colonization factors and their important 
metabolic abilities render them one of the major microbial players in gut colonization 
during the ﬁrst stages of life16. Proof of the genomic adaptation to their host is the 
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identiﬁcation of a varied arsenal of genes encoding enzymes that are involved in the 
breakdown of complex carbohydrates derived from the diet (e.g., plant polysaccharides) 
or from the host (e.g., mucin). These carbohydrates cannot be digested by host-derived 
enzymes and will thus reach the large intestine in an intact form providing a good 
environment for bifidobacteria to thrive. Identified genes with a potential role in the 
processes of colonization and adaptation to the gastrointestinal habitat include those 
codifying for enzymes conferring bile resistance, enzymes for the utilization of human 
milk oligosaccharides and dietary complex polysaccharides, adhesins that mediate 
binding to mucus, plasminogen and other host surface receptors,  components of pili, 
and possibly also exopolysaccharide components, inducible low pH resistance genes, 
and the LuxS enzyme of the activated methyl cycle of bacteria for recycling of S-
adenosylmethionine17.  
Several studies have assessed the changes in microbiota composition in the human gut 
after probiotic consumption. Most frequently, an increase in the proportion of the 
supplemented genera was found in feces, but without an effect on the composition and 
diversity of the main bacterial populations. This was the case in several intervention 
studies: 1) supplementation with L. acidophilus NCFM and B. lactis Bi-07 to children 
with atopic dermatitis led to increases in both species after intervention, indicating 
survival of the bacteria; however Bifidobacterium spp., L. mesenteroides and L. gasseri
determined by qPCR and abundances of the bacterial classes determined by 
pyrosequencing, including bacteroidetes, clostridia, actinobacteria, proteobacteria and 
verrucomicrobiae did not change after the intervention, and neither did richness and 
diversity estimates18, 2) probiotic cheese administration containing Lactobacilllus 
rhamnosus HN001 and Lactobacillus acidophilus NCFM to elderly volunteers resulted 
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in increased numbers of both species in the feces, while clostridial cluster XIV, F. 
prausnitzii and sulfate reducers measured by qPCR and Bifidobacterium genus, the 
Bacteroides–Prevotella group, the C. histolyticum group, A. muciniphila-like bacteria 
and the total bacteria analyzed with fluorescent in situ hybridization and flow cytometry 
did not show any significant changes19, 3) the synbiotic supplement Gut Balance TM
used in a study with healthy physically active adults increased by a factor of 9 the fecal 
L. paracasei numbers compared to the prebiotic product used as control, but total 
Lactobacilli, L. acidophilus, L. rhamnosus, B. lactis and E. coli measured by qPCR
remained unmodified20, and 4) the treatment with L. reuteri DSM 17938 in colicky 
infants (age 10-60 days) did not change the global composition of the microbiota at the 
phyla and taxa levels by pyrosequencing analysis21. 
On the other hand, other studies have reported wider changes in microbiota composition 
with probiotic administration.  Synbiotic supplementation based in Lactobacillus 
acidophilus NCFM and lactitol in elderly subjects resulted in an increase in total levels 
of bifidobacteria and lactobacilli22. B. lactis Bb12 supplementation increased the cell 
counts of bifidobacteria and reduced the cell counts of enterobacteria and clostridia in 
preterm infants23. Larsen et al. 24 described that the ratio of Bacteroides-Prevotella-
Porphyromonas group to Firmicutes was significantly increased after administration of 
Lactobacillus salivarius Ls-33 for 12 weeks in obese adolescents, although no 
statistically significant changes were observed in the number of bacteria of any of the 
groups analyzed. Lactobacillus paracasei subsp. paracasei LC01 (LC01), in a 4-week 
treatment period, reduced fecal Escherichia coli and increased Lactobacillus, 
Bifidobacterium, and Roseburia intestinalis in healthy adults25. Lactobacillus GG was 
shown to act on the dysbiosis found in patients with cirrhosis and minimal hepatic 
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encephalopathy by reducing Enterobacteriaceae and increasing Clostridiales Incertae 
Sedis XIV and Lachnospiraceae26. Daily ingestion of one or more food products 
enriched with Lactobacillus rhamnosus IMC 501® and Lactobacillus paracasei IMC 
502® during 12 weeks increased fecal lactobacilli and bifidobacteria of healthy adults27. 
Other evidences of gut microbiota changes by probiotic feeding have also emerged from 
animal studies as reviewed by Tsai et al28. 
Evidence from in vitro experiments also indicates that the interaction of probiotic 
bacteria with host epithelial cells promotes phenotypic changes in the bacteria that 
improve their mutualistic relationship. The contact of Lactobacillus casei ATCC 334 
with human intestinal epithelial cells promotes functional changes in the bacteria, which 
acquire a more immunosuppressive phenotype as demonstrated by the ability of L. casei
to generate functional regulatory T cells (CD4+CD25+FoxP3+) and production of the 
anti-inflammatory cytokine IL-1029. Cultivation of B. longum NCC2705 with intestinal 
epithelial cells has been also shown to induce adhesin expression30.  
Relationship between microbiota and obesity. Experimental evidence. 
Obesity is one of the main health issues around the world because of the high 
prevalence and its association with the metabolic syndrome and related pathologies such 
as hypertension, diabetes, fatty liver disease and cardiovascular disease among others. 
The negative impact on health is obviously associated with a diminished quality of life 
and high healthcare costs. In 2008, about one-third of the world's adult population 
(∼1.46 billion) was overweight, whereas the age-standardized prevalence of obesity was 
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9.8% in men and 13.8% in women; with wide variation between and within countries31. 
The combined effect of genetic and environmental factors on the obesity epidemic is 
generally accepted, including unhealthy dietary patterns and sedentary behaviors, 
typical of the obesogenic environment of modern society32. However, more recently, gut 
microbiota dysbiosis has been considered as an additional factor in obesity and type II 
diabetes mellitus development33. Novel methodologies have provided ways to 
exhaustively study the variety of microbial communities in the intestinal ecosystem and 
some evidences have emerged linking different microbial phylotypes and different 
bacterial species to obesity in humans34 and animals, especially in fecal transplantation 
experiments performed in germ-free animals35.  
The first metagenomic analysis of human intestinal microbiota reported that obese 
individuals have lower ratios of Bacteroidetes to Firmicutes34. This was consistent with 
the results from studies performed in gnotobiotic animals transplanted with the fecal 
microbiota of obese mice, which led to greater fat deposition compared with control 
mice transplanted from lean animals35. According to the results in animal models, the 
microbiome of obese animals has an increased capacity for energy harvest36.  
Although the hypothesis exists that microbiota might play a causative role in obesity, 
the opposite could be true and the dysbiosis might just be the result of the adaptation to 
a high fat and sugar diet37,38. However, both human and animal model studies have 
yielded conflicting results about the precise nature of the associations between 
microbiome composition and obesity. Recently, an extensive assessment of the 
relationship between body mass index (BMI) and the taxonomic composition of the gut 
microbiome was conducted in the Human Metagenomic Project (HMP) dataset, and the 
results were compared with those obtained in the other big metagenomic study of gut 
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microbiota –the MetaHIT study– and also with two other smaller studies that 
specifically sampled lean and obese individuals3, 34. The authors found no association 
between BMI and stool microbiome taxonomic composition or diversity in the HMP 
cohort39. They also found that inter-study variability far exceeded differences in 
composition between lean and obese individuals within each study, and concluded by 
suggesting that no simple taxonomic signature of obesity exists in the gut microbiome. 
The same conclusion was reached in a meta-analysis searching for indicator taxa in the 
microbiome and general features of the microbiota associated with obesity40. 
Intervention studies with probiotics in the management of obesity 
Based in the idea that different microbiota colonize the gut of normoweight and obese 
individuals, emphasis has been directed to carry out research studies aimed to provide 
weight management through probiotic administration, with the advantage that no 
secondary effects are expected from this kind of interventions; however, most of the 
research so far has been conducted in animal models of diet-induced obesity. Human 
intervention studies with the specific aim of obesity management have also been 
published, although in limited number. In this section we will focus on those studies 
conducted with bacterial strains of the genera Lactobacillus (phylum Firmicutes) and 
Bifidobacterium (phylum Actinobacteria). 
Animal studies 
Several studies carried out with similar methodologies have shown decreases in the 
body weight of mice and rats with high-fat diet-induced obesity and administered or 
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supplemented with one or a number of Lactobacillus and Bifidobacterium strains. 
Usually these experimental procedures are also accompanied by a decrease in fat tissue 
weight at several abdominal locations, and even an improvement of other features 
associated with obesity, such as insulin resistance, metabolic syndrome, inflammation 
or liver steatosis. Differences are, however, detected between strains on the results 
obtained and also regarding the potential mechanisms leading to the observed anti-
obesity effects. Modulation of fat absorption and excretion was shown in lean rats41 , 
reduction of endotoxemia and inflammation was reported in genetically or diet-induced 
obese rodents42,43,44,45,46,47, and very frequently, a modulation of the expression of genes 
involved in hepatic lipogenesis and/or adipose tissue lipolysis has been evidenced and 
suggested as the mechanism for the anti-obesity effects45,48,49,50,51,52, although the exact 
genes modulated will depend on the strain used. 
Effects on body weight, adiposity and metabolism 
In rodent models of obesity, the number of studies showing decreased body weight gain 
and reduced accumulation of fat deposits with probiotic treatments is much higher than 
that of studies that report no change in body weight and fat mass. In those studies in 
which the primary outcome is the anti-obesity effect, the supplementation period is 
usually longer than 10 weeks. 
Lactobacillus plantarum LG42 isolated from Gajami sik-hae, a traditional Korean 
fermented product, was shown to decrease food intake, weight gain, epididymal and 
back fat mass and serum and liver triglycerides when supplemented to high-fat diet-
induced C57BL/6j obese mice. This supplementation also decreased hepatic lipogenic 
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genes expression (LXR-α, SREBP-1, and ACC), whereas it increased the hepatic 
PPAR-α and CPT-1 mRNA levels, which up-regulate the expression of enzymes 
involved in fatty acid oxidation (Table 1). It also decreased expression of proteins 
involved in lipid anabolism in adipose tissue, such as PPAR-γ and C/EBP-α 51. A 
similar reduction in fat mass and the modulation of lipogenic and lipolytic gene 
expression in the liver were found in an obesity model of mice fed a high-sucrose diet 
and supplemented with Lactobacillus gasseri BNR17 during 10 weeks50. Another 
supplementation with Lactobacillus gasseri SBT2055 for 24 weeks to mice on a high-
fat diet during that period resulted in a significant reduction in body weight and fat 
tissue mass and a relatively lowered level of triglyceride content in the liver, parallel to 
reduced expression of lipogenic genes, including ACC1, FAS and SREBP-1, while no 
changes were observed in lipolytic genes (CPT-1-α, PPAR-α, or UCP-2)52. On the 
contrary, in another experiment in which mice received Lactobacillus curvatus HY7601 
and Lactobacillus plantarum KY1032 during 10 weeks, CPT-1 and other fatty acid 
oxidation-related genes were up-regulated, together with a reduction in body weight and 
adiposity, plasma insulin, leptin and total cholesterol, in comparison with the control 
group45. In healthy mice fed a standard diet, Ji et al.49 found that supplementation 
during 3 weeks with either L. rhamnosus GG or L. sakei decreased epididymal fat and 
the expression of ACC, fatty acid synthase (FAS), and stearoyl-CoA desaturase (SCD)-
1 genes in the liver. Finally, also in young healthy mice, Angelakis et al.54 described 
that the intragastrical inoculation of one or two doses of L. ingluviei led to increases in 
weight gain and liver weight and increased the expression of lipogenic markers in liver 
such as FAS and SREBP-1c, in contrast with the wide majority of findings from 
probiotic studies performed in obesity-induced models. The efficacy of different 
Lactobacillus species as growth promoters of the young animal in the livestock and 
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poultry industry has been explored55 and might be related to these specific and 
controversial results.  
In fact, the work of D. Raoult’s team54,56 has elicited considerable debate among those 
involved in probiotic research. They support that there is enough evidence to suggest 
that some probiotic strains of Lactobacillus induce weight gain in lean humans and 
animals while other strains exhibit a weight-loss effect in overweight/obese humans and 
animals and they advise that it would be a negligence to disregard the hypothesis that 
probiotics might be linked to human obesity56,57. For those opposed to this opinion, the 
evidence points towards a promotion of growth and lean body mass, but not adiposity58
and several other weaknesses have been pointed out against the evidence on which the 
hypothesis was relied on59. 
Other putative mechanisms have been proposed for the anti-obesity effects of 
Lactobacilli. One of them is an increase in the production of ANGPTL4, a lipoprotein 
lipase inhibitor that controls triglyceride deposition into adipocytes, as supported by the 
study by Aronsson and colleagues60. Feeding L. paracasei ssp. paracasei F19 to high-
fat diet-induced obese mice reduced body fat while increasing circulating ANGPTL4. 
Other mechanism, suggested by Tanida and colleagues61, is an enhanced lipolysis linked 
to increased sympathetic nerve activity in adipose tissue and supported by the increase 
in plasma free fatty acids; both leading to reduced body and abdominal fat weights in 
mice fed Lactobacillus paracasei ST11. On the other hand, reductions in the absorption 
of dietary fat have also been reported with probiotic supplementation. In this sense, L. 
gasseri SBT2055 led to a decrease in mesenteric fat weight and cholesterol levels, and 
an increase in fatty acid excretion in lean rats after 8 weeks of feeding, which the 
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authors explained through a decreased absorption of dietary fat41. This study, however, 
did not find changes in body fat when the supplementation was made on obese Zucker 
rats. This result is in contrast with those reported by Miyoshi and colleagues52 using the 
same strain; however, Miyoshi’s experiment was not performed in genetically obese 
rats, but in mice fed a high-fat diet, and also the duration of the supplementation was 
much longer (24 weeks). Decrease in visceral fat and triglyceride in the liver with 
increased fecal triglycerides in KK-A(y) mice on a high fat diet and supplemented with 
Lactobacillus gasseri NT have also been reported by Yonejima and colleagues, who 
explain the findings through a reduction of lipid digestion/absorption62. Recently, the 
expression of cloned bile salt hydrolase from  Lactobacillus salivarius in mice gut has 
also been demonstrated to regulate transcription of genes involved in lipid and 
cholesterol metabolism,  and has an impact in adiposity and weight control63. 
The existing differences at the strain level are well exemplified in Fak and Bäckhed’s  
study53 in a mouse model of obesity (Apoe-/- mice) in which they tested the anti-
obesity, anti-inflammatory and anti-atherogenic effects of three different strains of L. 
reuteri. They found that only one of the strains showed anti-obesity effects, apparently 
linked to liver lipolytic activity; however, no anti-inflammatory or anti-atherosclerotic 
effect was achieved irrespective of the treatment. 
With regards to bifidobacteria, high-fat or Western-type diets have been shown to 
reduce their presence in the guts of rodent models of dietary obesity64. Supplements of 
prebiotics, in particular oligofructose and inulin-type fructans, can increase their 
numbers64,65,66, and concomitantly reduce body weight and adipose tissue depots and 
improve glucose tolerance when administered to high-fat diet-fed animals64,66. It was 
suggested that this effect could be mediated by increases in the expression of glucagon-
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like peptide 1 (GLP-1)67; actually, higher levels of proglucagon mRNA have been found 
in the guts of prebiotic-treated animals64,65, as well as higher GLP-1 plasma levels62. 
GLP-1 has been shown to induce satiety68,69 ; however, in most studies using either 
prebiotics or bifidobacteria supplements, average caloric intake of the animals did not 
decrease significantly64,66,70,71,72,73. An exception is the study by Bomhof and 
colleagues74, where animals fed oligofructose, but not those given Bifidobacterium 
animalis subsp. lactis, had overall lower energy intake, body weight gain and fat 
content. Interestingly, only oligofructose treatment was accompanied by elevated GLP-
2 levels. 
Other mechanisms have been proposed to explain the anti-obesity effects of 
bifidobacteria-stimulating prebiotics. For example, Dewulf and colleagues found that 
inulin supplementation to dietary obese mice increased basal lipolysis in subcutaneous 
adipose tissue, which had been blunted by the high-fat diet, together with reduced 
expression of GPR4366, which is an inhibitor of lipolysis75 and has been also found to 
stimulate adipocyte differentiation76. In addition, expression of other genes involved in 
adipocyte differentiation and fat storage, i.e., aP2, CEBPα and LPL, was also reduced 
after inulin supplementation66. The question arises, however, whether the effects of 
prebiotics are due to increased bifidobacteria populations or the prebiotics themselves, 
or what the actual role of these bacteria is. For example, in the study by Bomhof, 
prebiotic supplementation was more efficient than probiotics at changing composition 
of microbiota in the rats’ guts74. 
Direct interventions with bifidobacteria have also rendered significant anti-obesity 
results. Different studies using several Bifidobacterium strains, such as B. breve B-370 , 
B. L66-571, B. pseudocatenulatum and B. longum72,43 , B. adolescentis77, B. lactis 42078, 
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or B. animalis subsp. lactis73 have reported reductions in high-fat diet-induced increases 
in body weight gain and fat content. In addition, most of these studies found as well 
reductions in circulating levels of glucose and insulin, and/or improved glucose 
tolerance43, 70,72,73,74 ,78 . Furthermore, bifidobacteria seem to be effective at ameliorating 
other features of the metabolic syndrome, like elevated plasma triglycerides43, 71 and 
cholesterol70,71 , and even blood pressure43 . Some of the mechanisms proposed to 
explain the beneficial effects of bifidobacteria coincide with those attributed to 
prebiotics, as mentioned earlier. Kondo70 found that administration of Bifidobacterium 
breve B-3 (109 colony-forming units (CFU)/d) increased proglucagon and Fiaf 
expression in the gut, and adiponectin expression in adipose tissue. Kondo and co-
workers70 suggested that GLP-1 and -2, together with increased adiponectin expression, 
might contribute to the enhanced insulin sensitivity observed, while Fiaf could 
contribute to decrease fat deposition in adipose tissue, as it inhibits LPL. Another 
mechanism proposed by the authors was the conversion of linoleic acid to conjugated 
linoleic acid (CLA) by the bifidobacteria, which had previously been reported79,80, as 
there is evidence in the literature for an anti-obesity effect of this fatty acid81 . 
It could be argued (and in fact it has been) that the models employed for the study of the 
effects of probiotics on obesity all introduce a confounding factor in the form of the 
high-fat diets, as diet is one of the most influential factors for altering microbiota 
composition. Even though the vast majority of studies have used diet to induce obesity, 
there are a few cases when obesity has been achieved by other means, and they are 
worth mentioning. For example, in the work by Savcheniuk and co-workers82, rats were 
made obese by injections of monosodium glutamate (MSG) during the first 10 days of 
life, and fed afterwards on standard chow. Administration of a probiotic mixture of L. 
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casei IMVB-7280, B. animalis VKL and B. animalis VKB did not change body weight, 
but partially reduced visceral fat mass and serum triglycerides; it also completely 
reduced total cholesterol, and partially restored normal levels of the different fractions 
(VLDL, LDL and HDL cholesterol). In addition, the probiotic normalized serum 
adiponectin levels and leptin expression in adipose tissue82. On the other hand, 
supplements of either L. paracasei (CNCM I-4034), L. rhamnosus (CNCM I-4036), B. 
breve (CNCM I-4035), or a mixture of L. paracasei and B. breve administered to 
genetically obese Zucker rats did not result in significant reductions of body weight 
gain, improvement of markers of insulin sensitivity, or any other serum parameter; 
however, all treatments reduced total lipid content in the liver of the obese rats47. 
It is also worth noting that different effects have been observed depending on the strain 
used. For example, in the experiment by Yin and colleagues71, rats with high-fat diet-
induced obesity were treated with four strains of bifidobacteria, all obtained from feces 
of healthy volunteers, and named L66-5, L75-4, M13-4 and FS31-12. The authors found 
that B. L66-5 blunted the diet-induced increase in body weight, while B. M13-4 further 
enhanced it. And whereas no differences in relative body fat content, glucose or insulin 
levels were found between treatments, and all bifidobacteria reduced serum 
triglycerides, only B. L66-5 and B. FS31-12 reduced cholesterol levels as well71. 
Effect on liver steatosis and inflammation 
Apart from their effects on body weight and fat, and on glucose and lipid metabolism, 
probiotics have been found to improve other conditions related to obesity, such as 
inflammation and liver steatosis. Cani et al. (2008)33, have provided evidence that gut 
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bacteria are involved in metabolic endotoxemia and adipose tissue inflammation in 
obese animals and have also shown that the mechanisms involved in the development of 
metabolic endotoxemia are associated with an increased intestinal permeability. 
Activation of Toll-like receptors in macrophage and epithelial cells by LPS is 
responsible for the induction of inflammation. Thus, improvement in gut barrier 
function by probiotic bacteria would reduce the chances of endotoxemia and reverse or 
impede those putative causes of obesity development. In fact, modulation of the 
expression of inflammatory genes has been analyzed in the high-fat diet-induced obesity 
model after probiotic supplementation.  
Lactobacillus gasseri SBT2055 suplemented to mice on a high-fat diet in the study of 
Miyoshi et al. described previously52, not only reduced fat tissue and the expression of 
lipogenic genes but it also inhibited pro-inflammatory CCL2 gene expression in adipose 
tissue. Similarly, the beneficial findings related to weight, adiposity and fatty acid 
oxidation-related genes in Park et al.’s study45 with Lactobacillus curvatus HY7601 and 
Lactobacillus plantarum KY1032, were accompanied by the down-regulation of pro-
inflammatory genes in adipose tissue (TNF-α, IL-1β, IL-6 and MCP-1). Also in a mouse 
model of fructose-induced obesity, supplementation of Lactobacillus rhamnosus GG
has proven to restore barrier permeability at the duodenal level, to lower 
lipopolysaccharide (LPS) in portal vein and to reduce liver steatosis and inflammation, 
as measured by neutral lipid assay and pro-inflammatory cytokine expression, 
respectively. Although no differences in weight were observed among groups, there was 
a trend for a decreased weight gain in the supplemented groups46. Reduction in 
endotoxemia (plasma LPS) was also reported by Naito and colleagues44 in mice on a 
high-fat diet supplemented with L. casei Shirota despite no changes in intra-abdominal 
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fat weight, which might perhaps be due to a short duration of the supplementation (4 
weeks)44. 
Oral probiotic treatment with VSL#3 significantly improved the high fat diet-induced 
hepatic NKT cell depletion, insulin resistance and hepatic steatosis in mice42. These 
effects of probiotics are likely due to increased hepatic NKT cell numbers and reduced 
inflammatory signaling. High-dose VSL#3 (1.5×109 CFU/day) was more effective than 
low-dose VSL#3 (1.5×108 CFU/day) and B. infantis (1.5×109 CFU/day) at improving 
hepatic NKT cell depletion and steatosis. Weight gain was also significantly reduced in 
animals fed the high-dose VSL#3 compared to the control. Lipid extracts from VSL#3 
also stimulated NKT cells in vivo and in vitro83. The results suggest that specific 
probiotic strains can have profound effects on hepatic NKT cells and steatosis, and that 
glycolipid antigens from bacteria can modulate the functionality of NKT cells83. 
A study that measured glucose –insulin homeostasis, hepatic steatosis and the 
modulation of the structure of the HFD-disrupted gut microbiota by three candidate 
probiotics using 454 pyrosecuencing of bacterial 16S rRNA genes showed that each 
strain employed (Lactobacillus paracasei CNCM I-4270, L. rhamnosus I-3690 and 
Bifidobacterium animalis subsp. lactis I-2494) attenuated weight gain and macrophage 
infiltration into epididymal adipose tissue and markedly improved glucose –insulin 
homeostasis and hepatic steatosis73. Gut microbiota shifted towards that of lean mice 
fed a normal diet; however, each strain changed a different set of the 49 altered 
operational taxonomic units (OTUs) defined as functionally relevant by their correlation 
with metabolic syndrome parameters. L. paracasei and L. rhamnosus increased cecal 
acetate but did not affect circulating LPS-binding protein, which is in contrast with the 
results reported by Plaza-Díaz et al. (2014)47, who found that different strains of the 
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same species decreased serum LPS in obese Zucker rats. The results support the notion 
that the beneficial effects on obesity-related comorbidities are mediated through strain-
specific impacts on metabolic syndrome-associated phylotypes of gut microbiota73. 
In relation to bifidobacteria, there seems to be a relationship between their presence in 
the gut and levels of inflammatory markers, in both liver and intestine. It has been 
proposed that bifidobacteria can stimulate the expression of tight-junction proteins in 
the epithelium, decreasing the permeability of the gut and thus protecting the organism 
from pathogens, which leads to increased circulating LPS levels, or endotoxemia, and in 
consequence inflammation64,65,84 . Decreased numbers of bifidobacteria associated with 
high-fat diet feeding have been linked with increased gut permeability and elevated 
levels of LPS and endotoxemia. The use of prebiotics to increase the numbers of 
endogenous bifidobacteria64,65, as well as that of peptides from exogenous bifidobacteria 
strains, seems to be effective in enhancing the expression of tight-junction proteins, and 
reducing gut permeability and inflammation65,84,85. Administration of prebiotics 
(oligofructose) has also been shown to reduce plasma levels of cytokines (IL-1β, TNF-
α, MCP-1, MIP-1a, IFN-γ, IL-10, IL-15 and IL-18), expression in the liver of markers 
of inflammation (PAI-1, TNF-α), macrophage infiltration (CD68, TLR4), and oxidative 
stress (NADPHox, iNOS)86, and expression of TLR4 and F4/80 in adipose tissue66. 
As with the anti-obesity effects, doubts may arise whether the effects are mediated by 
the prebiotics themselves or by the bifidobacteria. Again, the work by Bomhof, which 
compared the effects of prebiotics, probiotics and their combination, showed that only 
rats receiving oligofructose had significant elevations on tight-junction protein 1 
expression, while administration of B. animals subsp. lactis BB-12 alone did not exert a 
significant effect on the levels of this protein74. However, earlier studies showed the 
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efficacy of probiotic supplements in reducing endotoxemia87  and improving mucosal 
integrity88. In models of diet-induced obesity, bifidobacteria have been found to 
counteract high-fat diet induced hepatomegaly (with a mixture of B. pseudocatenulatum 
SPM 1204, B. longum SPM 1205 and B. longum SPM 120772 and with B. longum on its 
own77), and to partially or totally abolish lipid deposition in hepatocytes, contributing to 
prevent or reverse liver steatosis (with B. adolescentis77,89; with Bifidobacteria L66-5,
L75-4, M13-4 and FS31-1271; with L. paracasei CNCM I-4270, L. rhamnosus CNCM I-
3690 and B. animalis subsp. lactis CNCM I-2494, independently73). Also in non-
dietary, genetically obese Zucker rats, reduced triglyceride and total lipid content in 
liver was observed following administration of B. breve CNCM I-4035, alone or in 
combination with L. paracasei CNCM I-403447. 
In addition, B. lactis 420 has been shown to reduce the levels of inflammatory markers 
in the liver (TNF-α and IL-1β) and muscle (IL-1β) in mice with diet-induced mild 
diabetes treated with the probiotic78. For its part, B. adolescentis was reported to reduce 
neutrophil infiltration and liver damage in the liver of mice made obese by a Western-
type diet. And even when no changes in portal levels of LPS were found, expression of 
TLR4, MCP-1, MIP-3, NF-κB activity, and markers of lipid peroxidation were reduced 
in the liver of treated animals89. Furthermore, amelioration of systemic inflammation, in 
the form of reduced LPS levels in serum, has been reported after treatments with B. 
longum43, B. lactis 42078, B. breve CNCM I-403547, and B. animalis subsp. Lactis73. B. 
breve CNCM I-4035 resulted also in lower levels of serum TNF-α47. This effect is likely 
a consequence of reduced inflammation and/or improved epithelial integrity in the guts 
of the treated animals. B. longum can partially decrease IL-1β expression in small 
intestine, concomitant with total improvement of its inflammatory status43. Chen and 
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colleagues 43 suggested that it was mediated by elevated expression of Reg-I, which is 
thought to help repair tissue damage in the small intestine43,90. For its part, B. 
adolescentis has been reported to improve the integrity of the gut epithelium as well, 
through elevated expression of tight-junction proteins, like occludin and ZO-1, in the 
duodenum89. Another mechanism proposed for the protective actions of probiotics in 
the intestine is the formation of carboxylic acids, like butyrate and propionate, as they 
may exert beneficial effects on intestinal health, such as increase of the mucosal 
integrity or reduction of colon cancer risk91. However, these effects should be expected 
to vary greatly depending on the probiotic strain used and on the diet(s) with which they 
are administered. Nilsson and colleagues compared the effects of combining different 
prebiotics (inulin, pectin and lactitol) with different probiotics (B. lactis Bb-12 and L. 
salivarus UCC500) in the concentrations of carboxylic acids in the intestine of rats. 
Each combination provided a different outcome; in particular, when administered with 
inulin, Bb-12 increased carboxylic acids in the cecum, resulting in higher levels of 
propionate, but decreased their presence in the distal colon, suggesting that Bb-12 
induced stimulation of inulin fermentation preferentially in the cecum. In turn, when 
Bb-12 was provided together with pectin, carboxylic acids in the colon increased, and 
when given with lactitol, their absorption in the colon was suggested to be enhanced91. 
The precise consequences of these different outcomes for intestinal health need yet to be 
unraveled, but they highlight the importance of considering the variability and 
complexity of the relationships established between host and microbiota, between 
microbiota and diet, and also between the different bacterial populations within an 
organism. 
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In this sense, and similarly to what was discussed earlier about the effects of probiotics 
on body weight and fat, each probiotic strain has a different impact on liver, intestine 
and inflammatory status of the host. In the study by Yin and coworkers, B. L66-5, B. 
L75-4, B. M13-4 and B. FS31-12 could all ameliorate liver steatosis, but B. L66-5 and B. 
FS31-12 provided better results. Authors even proposed different mechanisms of action 
for the different strains: they suggested that while B. L66-5 could decrease fat 
deposition in general, the reason why treatment with B. M13-4 had resulted in higher 
body weight but reduced liver steatosis was a redistribution of fat deposition away from 
the liver and towards adipose tissue, highlighting the importance of choosing the 
appropriate strain depending on the nature of the condition to treat71. When comparing 
L. paracasei CNCM I-4270, L. rhamnosus CNCM I-3690, and B. animalis subsp. lactis
CNCM I-2494, Wang and colleagues observed that all probiotics reduced the presence 
of macrophages and crown-like structures in adipose tissue, but only B. animalis 
reduced TNF-α levels in adipose tissue and liver and systemic endotoxemia73. Finally, 
although in the study by Plaza-Diaz L.47 paracasei CNCM I-4034, B. breve CNCM I-
4035, L. rhamnosus CNCM I-4036, and the mixture of L. paracasei and B. breve could 
all reduce total liver lipids in Zucker rats, liver triglyceride content was decreased by L. 
paracasei and B. breve, but not L. rhamnosus; and while serum TNF-α and LPS 
decreased with L. paracasei and B. breve treatments, serum IL-6 only did with L. 
paracasei47. 
Human studies 
Several studies have been performed with Lactobacilllus gasseri SBT2055 in Japanese 
adults. In subjects with large visceral fat areas the intervention with fermented milk 
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containing 108 CFU/day during 12 weeks significantly reduced abdominal adiposity 
measured by computed tomography, and also other measures such as body weight, BMI 
and hip and waist circumferences92,93 . The decrease in weight in 12 weeks was, 
however, not a big one (1 kg approx.). The same strain tested in non-obese 
hypertriglyceridemic subjects revealed that 4-week supplementation significantly 
diminished the postprandial triglyceride and free fatty acid response to an oral fat-
loading test in a placebo-controlled, repeated measures trial, without a change in 
weight94. These different outcomes could be due to the normal weight status of the 
subjects or the shorter duration of the supplementation in comparison with the above 
mentioned studies. The effect on weight and body composition of these interventions as 
well as those performed with other strains in humans have been summarizes in Table 2.  
A decrease in weight and waist and hip circumferences were observed in Korean adults 
with high BMI that received L. gasseri BNR17 for 12 weeks; however, no differences 
in these parameters were found between the treated (6×1010 CFU/day) and placebo 
groups95. As in the previously mentioned studies, only 1 kg of weight was decreased 
over the study period. L. amylovorous has also shown a significant decrease in total fat 
mass in overweight subjects that consumed 109 CFU/day during 43 days; however, no 
change in body weight or lean body mass was observed in this study96. 
An interesting follow-up study recently reported the effects on body composition and 
metabolic markers of an intervention with L. paracasei ssp. paracasei F19 performed 
during weaning97 and evaluated at school age 98. While lower levels of palmitoleic acid, 
a marker linked to abdominal fat, were found after the intervention in treated infants, 
having received LF19 during infancy did not modulate BMI z-score, sagittal abdominal 
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diameter measured by DEXA, measures of fat and fat-free mass, growth, or any of the 
assessed metabolic markers at school age. This is interesting as evidence that long-term 
effect of probiotic administration is not granted once discontinued.  
To sum up, results from human intervention studies with lactobacilli of sufficient length 
and with weight or fat mass as main outcome are still scarce. These mainly used L. 
gasseri strains and suggest an overall modest effect on weight loss, which seems to be 
due to fat mass loss specifically. However, it remains to be clarified how long should 
the intervention be and whether the anti-obesity effects are in fact limited to subjects 
who are obese and/or hyperlipidemic prior to the intervention. 
Even fewer studies have been found in relation to the use of bifidobacteria. As observed 
with animals, some of them do not use directly the probiotics, but prebiotics known to 
increase bifidobacteria populations in the host gut. These studies, however, vary in their 
design, duration, and characteristics of the subjects, and of course also in their 
outcomes. In a study on healthy normoweight adults (5 men and 5 women, 21-38 years 
old), the effects of a prebiotic supplement (Orafti Synergy1, soluble fibre consisting of a 
mixture of glucosyl-(fructosyl)n-fructose and (fructosyl)m-fructose extracted from 
chicory roots) were studied on hunger perception and satiety-related peptides. A 
dextrin-maltose placebo was used as control, and the treatment lasted 2 weeks. The 
prebiotic but not the placebo lowered hunger perception 3 hours after the previous meal 
(breakfast), although no significant changes in food intake were reported for either 
group. There were also no changes in absolute levels of satiety hormones, but 
significantly higher relative increases in PYY and GLP-1 were observed in the prebiotic 
group 15 minutes after breakfast; however, levels in both groups converged shortly 
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afterwards. Barely any changes were found between groups in markers of insulin 
sensitivity, only a lower glucose area under the curve after the meal86. 
Parnell and Reimer studied as well the effects of prebiotics on hunger and satiety, but 
they conducted their study on 48 overweight and obese Canadian volunteers (20-70 
years of age). Participants received either a supplement of oligofructose (21 g/d; 
Raftilose P95, Quadra Chemicals Ltd, Burlington, Canada) or a dextrin-maltose placebo 
for 12 weeks. At the end of the treatment, levels of PYY in response to a meal tolerance 
test were increased and those of ghrelin decreased in the prebiotic group when 
compared to a similar test prior to the intervention, but it was not the case in the control 
group. This was accompanied by decreased total intake and significantly higher weight 
loss (due to fat mass, as measured by DXA) in the prebiotic group compared with the 
control. Absolute concentrations of glucose and insulin were also reduced in the 
prebiotic group99. 
In relation to interventions with probiotics, in a study with overweight volunteers, 
researchers compared the effect of a herbal compound (bofutsushosan, or BTS) used in 
Asia to treat obesity, with and without a combination of probiotics (Streptococcus 
thermophilus KCTC 11870BP, L. plantarum KCTC 10782BP, L. acidophilus KCTC 
11906BP, L. rhamnosus KCTC 12202BP, B. lactis KCTC 11904BP, B. longum KCTC 
12200BP and B. breve KCTC 12201BP). Thirty-six females (19-65 years) with BMI>25 
kg/m2 and waist circumference >85 cm were given either BTS or BTS+probiotics for 8 
weeks. Both groups experienced reductions in body weight, BMI, fat percentage, waist 
circumference and total cholesterol, and no differences were found between groups. 
However, while HDL-cholesterol decreased with BTS treatment, it increased with 
BTS+probiotics. As there was no group with probiotics without BTS, the lack of 
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differences in body weight and fat between groups in this study does not prove a lack of 
effect of the probiotics on these parameters, only that the potential actions of BTS and 
the bacteria mixture were not additive. In fact, the presence of B. breve in the gut 
microbiota showed a negative correlation with endotoxin levels, which in turn were 
positively correlated with body weight, BMI, and fat mass; and numbers of B. longum 
were negatively correlated with body weight100.  
Also interesting is the study by Ilmonen and colleagues, a study on 185 pregnant Finish 
women receiving either dietary counselling plus probiotics (L. rhamnosus GG and B. 
lactis), dietary counselling plus placebo, or placebo alone. Treatments started during the 
first trimester of pregnancy and finished at the end of exclusive breastfeeding, 
maximum 6 months after giving birth. Results showed that probiotics plus counselling 
reduced the risk of central fat accumulation 6 months after given birth, biceps skinfold 
thickness and waist circumference at 12 months, and blood glucose levels both at 6 and 
12 months post-partum, compared to the other treatments101. 
One important issue to consider when evaluating the theoretical effect of the 
consumption of a given probiotic is the capacity of response of the individual. In this 
sense, “the bandwidth of health” paradigm proposes that, despite greater inter-individual 
variability measured through transcriptomic analyses compared with the change induced 
by probiotics consumption, the response to probiotics also occurs in a conserved manner 
across participants; however, the consequences of these responses in terms of their 
physiological relevance may depend strongly on the basal molecular make-up at the 
start of the intervention14,102. Measuring with current –omics methods the molecular 
signature of the person provides the way to select individuals most likely to respond to 
probiotics with a defined biological activity which has been proven either in vitro or in 
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animal models. On the other hand, linking the losing weight effect of a probiotic 
therapy with a change in the gut microbiota seems like a key point to establish probiotic 
usefulness against obesity, however, the cross-talk between microbes and host cells in 
the gut is complex and the mechanisms by which these interactions lead to obesity and 
metabolic disease are multiple and, so far, only starting to be disentangled (see recent 
review by Cani & Everard, 2015)103. Even when a change in the overall composition of 
the microbiota is not proven after a dietary intervention, other changes, such as mucin 
layer depth, antimicrobial peptide production, increased abundance of a single 
beneficial bacterial species or a change in metabolites in the bacteria or the host cells 
could influence obesity and metabolic alterations. So far, not a single human clinical 
trial with a probiotic has found changes in microbiota and weight simultaneously and 
occurring exclusively in the group receiving the probiotic. Figure 1 depicts potential 
influencial factors affecting the relationship between changes in microbiota and changes 
in weight induced by probiotic treatment. 
Concluding remarks 
While the study of the microbiota has emerged as an outstanding research field with 
great repercussion for health, it seems to be an intriguing one, difficult to comprehend 
in order to be able to practice successful, personalized interventions. The number of 
different microbial species that can be found in the gut is huge and the interactions 
between them and with the host cells need to be further explained so that probiotic 
strains can be used with a rationale. As attractive as the use of probiotics may seem to 
counteract the obesity problem, we are still far from being able to give guidelines for its 
clinical application. In addition, many more placebo-controlled, randomized clinical 
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trials are warranted which place the scientific knowledge to a comfortable level of 
evidence regarding specific strains, length of treatment, and dose that need to be 
administered. This advice, however, is probably bound to be effective only when taking 
in consideration the current microbial communities, metabolic alterations and even 
genetic background of each particular individual, and perhaps, also paying attention to 
life-style habits that are already known to influence the gut ecosystem. 
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Table 1. Summary of intervention studies with Lactobacillus spp. strains in animal models assessing expression of genes involved in lipid 
metabolism in the liver. 
Reference Experimental model Lactobacillus strain Change in 
weight 
Change in 
fat mass 
Liver lipolytic 
genes (mRNA) 
Liver lipogenic 
genes (mRNA) 
Park et al., 
201451
HFD obesity model, 12 
wk. 
Lactobacillus plantarum
LG42 
Yes Yes >PPAR-alpha and 
CPT-I  
< LXRalpha, 
SREBP-1, and 
ACC  
Miyoshi  et al., 
201452
HFD obesity model, 24 
wk. 
Lactobacillus gasseri
SBT2055 
Yes yes No change CPT1-
alpha, PPAR-alpha, 
UCP2 
Trends to < ACC1, 
FAS and SREBP1 
Park et al., 
201345
HFD obesity model, 8 wk 
and subsequent probiotic 
supplementation for 10 
wk. 
Lactobacillus curvatus
HY7601 and 
Lactobacillus plantarum
KY1032 
Yes Yes > PGC1-alpha, 
CPT1, CPT2, 
ACOX1 
- 
Kang et al., 
201350
HSD obesity model, 10 
wk. 
Lactobacillus gasseri
BNR17 
Yes Yes >ACO, CPT1, 
PPARalpha, 
PPARgamma 
< SREBP-1, ACC 
Fak and 
Bäckhed, 
201253
HFD + Apoe-/- Metabolic 
syndrome model, 12 wk. 
3 different strains of L. 
reuteri tested separately: 
L. reuteri ATCC PTA 
4659, or DSM 17938 or 
DSM L6798 
Yes (only for 
ATCC PTA 
4659) 
Yes (only 
for ATCC 
PTA 4659) 
>CPT1a (only for 
ATCC) 
No change in  FAS 
or ACC 
Ji et al., 201249 Healthy mice, standard 
diet, 3 wk 
Two treatments: 
L. rhamnosus GG 
L. sakei NR28 
< weight gain 
(only L.
sakei). 
Yes  - < FAS, ACC, 
SCD-1 
Angelakis et al., 
201254
Healthy 3 wk. old mice, 
standard diet, (single or 
double gastric inoculation, 
days 0 and 7th). 
L. ingluviei (single or 
double inoculation) 
increased 
weight gain 
with L.
ingluviei
inoculation 
- - > FAS, SREBP-1 
Lee et al., 
200648
Diet induced obese mice, 8 
wk. 
L. rhamnosus PL60 Yes Yes >UCP2 - 
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Table 2. Summary of intervention studies on the effect of different probiotics on weight and body compositions in humans. 
Ref. Design Subjects Probiotic strain and duration of intervention Anthropometric parameters Metabolic Changes 
92,93 multicenter 
DBPCRa
n= 87 
Obese 
S. thermophilus, L. delbrueckii 
ssp. bulgaricus and 
L. gasseri SBT2055 (1011 cfu/d.), 12 wk. 
↓Weight, BMI, abdominal 
visceral fat area and hip and 
waist circumferences 
- 
94 SBPCb n=20 
Adults with 
TAG200mg/dl, 
glucose100mg/dl 
S. thermophilus, L. delbrueckii 
ssp. bulgaricus and 
L. gasseri SBT2055 (1011 cfu/d.), 4wk. 
No change in weight or 
BMI 
↓Postprandial serum non-
esterified fatty acid (NEFA) 
and triacylglycerol (TAG) 
levels 
95 DBPCR n= 62 
Obese 
L. gasseri BNR17 (6 x 1010 cfu/d.), 12wk. ↓Weight and waist and hip 
circumferences 
No change in glucose, insulin 
and lipid profile 
96 DBPCR 
cross-over. 
n=28 
Obese 
Yogurt; yogurt + L. amylovorous (LA) (1.39 x 
109 cfu/d.); yogurt + L. Fermentun (LF) (1.08 x  
109 cfu /d.), 43 d. 
↓Total fat mass with LA ↓Abundance of Clostridial 
cluster IV with LA, 
↑Abundance of Lactobacillus
spp. in LF and LA 
98 DBPCR 
follow-up. 
n= 179 
Children 8-9y 
L. paracasei ssp. paracasei (108 cfu/d.), from 
4th to 13th month of age 
No change in BMI z-score, 
fat and lean mass (DEXA) 
No change in glucose, 
insulin, lipid profile, hepatic 
parameters 
100 DBPCR n=36  
Overweight 
females 
Herbal compound + (S thermophilus KCTC 
11870BP + L. plantarum KCTC 10782BP + L. 
acidophilus KCTC 11906BP + L. rhamnosus
KCTC 12202BP + B. lactis KCTC 11904BP + 
B. longum KCTC 12200BP + B. breve KCTC 
12201BP (5x1012 cfu/d.)), 8 wk. 
↓Weight, BMI, fat mass 
(%), waist circumference, 
but also in prebiotic only 
(herbal compound) group 
↓Total cholesterol, but also in 
prebiotic only (herbal 
compound) group. 
↑ HDL-cholesterol in herbal 
compound + probiotic 
101 DBPCR n=185  
Pregnant women 
L. rhamnosus GG (ATCC 53103) (1010 cfu/d.)  
and B. lactis Bb12 (1010 cfu/d.), from first 
trimester to end of exclusive breastfeeding 
↓Risk of central adiposity 6 
mo. postpartum (waist 
circumference >80cm) 
↓Glucose levels at 6 and 12 
mo. postpartum 
aDBPCR: double-blind, placebo controlled, randomized  study;  bSBPC single-blind, placebo-controlled, within-subject, repeated-measures (all 
subject consumed first the control yogurt and after a wash-out period (4 wk.) the probiotic). 
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Figure 1. Factors that influence the relationship between changes in microbiota and 
changes in weight induced by probiotic treatment.
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